• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有K103N和Y181C替代的常见非核苷类逆转录酶抑制剂耐药突变的机制研究

Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.

作者信息

Lai Ming-Tain, Munshi Vandna, Lu Meiqing, Feng MeiZhen, Hrin-Solt Renee, McKenna Philip M, Hazuda Daria J, Miller Michael D

机构信息

Department of Antiviral Research, Merck Research Laboratories, West Point, PA 19486, USA.

出版信息

Viruses. 2016 Sep 23;8(10):263. doi: 10.3390/v8100263.

DOI:10.3390/v8100263
PMID:27669286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5086599/
Abstract

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a mainstay of therapy for human immunodeficiency type 1 virus (HIV-1) infections. However, their effectiveness can be hampered by the emergence of resistant mutations. To aid in designing effective NNRTIs against the resistant mutants, it is important to understand the resistance mechanism of the mutations. Here, we investigate the mechanism of the two most prevalent NNRTI-associated mutations with K103N or Y181C substitution. Virus and reverse transcriptase (RT) with K103N/Y188F, K103A, or K103E substitutions and with Y181F, Y188F, or Y181F/Y188F substitutions were employed to study the resistance mechanism of the K103N and Y181C mutants, respectively. Results showed that the virus and RT with K103N/Y188F substitutions displayed similar resistance levels to the virus and RT with K103N substitution versus NNRTIs. Virus and RT containing Y181F, Y188F, or Y181F/Y188F substitution exhibited either enhanced or similar susceptibility to NNRTIs compared with the wild type (WT) virus. These results suggest that the hydrogen bond between N103 and Y188 may not play an important role in the resistance of the K103N variant to NNRTIs. Furthermore, the results from the studies with the Y181 or Y188 variant provide the direct evidence that aromatic π-π stacking plays a crucial role in the binding of NNRTIs to RT.

摘要

非核苷类逆转录酶抑制剂(NNRTIs)是治疗人类免疫缺陷病毒1型(HIV-1)感染的主要药物。然而,耐药突变的出现会阻碍其疗效。为了辅助设计针对耐药突变体的有效NNRTIs,了解突变的耐药机制很重要。在此,我们研究了两种最常见的与NNRTIs相关的K103N或Y181C替代突变的机制。分别使用具有K103N/Y188F、K103A或K103E替代以及具有Y181F、Y188F或Y181F/Y188F替代的病毒和逆转录酶(RT)来研究K103N和Y181C突变体的耐药机制。结果显示,具有K103N/Y188F替代的病毒和RT与具有K103N替代的病毒和RT对NNRTIs的耐药水平相似。与野生型(WT)病毒相比,含有Y181F、Y188F或Y181F/Y188F替代的病毒和RT对NNRTIs表现出增强或相似的敏感性。这些结果表明,N103和Y188之间的氢键可能在K103N变体对NNRTIs的耐药性中不起重要作用。此外,对Y181或Y188变体的研究结果提供了直接证据,表明芳香族π-π堆积在NNRTIs与RT的结合中起关键作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/aacc7e1e820f/viruses-08-00263-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/09719dfbedd7/viruses-08-00263-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/2a6883ecda3b/viruses-08-00263-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/f1bb076670d9/viruses-08-00263-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/ce189e319c24/viruses-08-00263-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/aacc7e1e820f/viruses-08-00263-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/09719dfbedd7/viruses-08-00263-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/2a6883ecda3b/viruses-08-00263-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/f1bb076670d9/viruses-08-00263-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/ce189e319c24/viruses-08-00263-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8772/5086599/aacc7e1e820f/viruses-08-00263-g005.jpg

相似文献

1
Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.具有K103N和Y181C替代的常见非核苷类逆转录酶抑制剂耐药突变的机制研究
Viruses. 2016 Sep 23;8(10):263. doi: 10.3390/v8100263.
2
Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.HIV-1 非核苷类逆转录酶抑制剂突变 K103N 和 M230L 对病毒复制和酶功能的差异影响。
J Antimicrob Chemother. 2010 Nov;65(11):2291-9. doi: 10.1093/jac/dkq338. Epub 2010 Sep 18.
3
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.非核苷类逆转录酶抑制剂治疗失败患者病毒分离株中对依非韦伦表型耐药的基因型相关性
J Virol. 2001 Jun;75(11):4999-5008. doi: 10.1128/JVI.75.11.4999-5008.2001.
4
Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors.
J Antimicrob Chemother. 2001 Jul;48(1):113-6. doi: 10.1093/jac/48.1.113.
5
HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.HIV-1 逆转录酶连接亚结构域突变与对已批准的非核苷抑制剂的耐药性有关。
Antiviral Res. 2011 Nov;92(2):139-49. doi: 10.1016/j.antiviral.2011.08.020. Epub 2011 Aug 28.
6
A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.HIV-1 CRF08_BC亚型逆转录酶连接子结构域中的一种新型突变D404N赋予了对非核苷类逆转录酶抑制剂(NNRTIs)的交叉耐药性。
J Antimicrob Chemother. 2015 May;70(5):1381-90. doi: 10.1093/jac/dku565. Epub 2015 Jan 29.
7
Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains.HIV-1 CRF_BC毒株逆转录酶中NNRTI耐药关键位点的鉴定
PLoS One. 2014 Apr 17;9(4):e93804. doi: 10.1371/journal.pone.0093804. eCollection 2014.
8
Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.与 HIV-1 非核苷类逆转录酶抑制剂奈韦拉平、依非韦伦和依曲韦林相关的临床相关突变的对接分析和耐药性评估。
ChemMedChem. 2011 Dec 9;6(12):2203-13. doi: 10.1002/cmdc.201100362. Epub 2011 Sep 27.
9
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.携带可导致非核苷类逆转录酶和整合酶链转移抑制剂耐药突变的 HIV-1 中病毒适应性和药物敏感性的改变。
J Virol. 2014 Aug;88(16):9268-76. doi: 10.1128/JVI.00695-14. Epub 2014 Jun 4.
10
NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.1型人类免疫缺陷病毒逆转录酶第190位密码子上由非核苷类逆转录酶抑制剂(NNRTI)选择的突变降低了对司他夫定和齐多夫定的敏感性。
Antiviral Res. 2007 Nov;76(2):99-103. doi: 10.1016/j.antiviral.2007.06.002. Epub 2007 Jul 2.

引用本文的文献

1
Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles.开发具有改善的耐药性和药代动力学特征的增强型HIV-1非核苷类逆转录酶抑制剂。
Sci Adv. 2025 May 30;11(22):eadt8916. doi: 10.1126/sciadv.adt8916.
2
Kinetic coevolutionary models predict the temporal emergence of HIV-1 resistance mutations under drug selection pressure.动力学共进化模型预测了 HIV-1 耐药突变在药物选择压力下的时间出现。
Proc Natl Acad Sci U S A. 2024 Apr 9;121(15):e2316662121. doi: 10.1073/pnas.2316662121. Epub 2024 Apr 1.
3
Autophagy is induced and supports virus replication in Enterovirus A71-infected human primary neuronal cells.

本文引用的文献

1
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.多拉韦林在临床相关浓度下可抑制常见的非核苷类逆转录酶抑制剂相关突变体。
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2241-7. doi: 10.1128/AAC.02650-15. Print 2016 Apr.
2
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.新型HIV-1非核苷逆转录酶抑制剂MK-1439的体外特性研究
Antimicrob Agents Chemother. 2014;58(3):1652-63. doi: 10.1128/AAC.02403-13. Epub 2013 Dec 30.
3
HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.
自噬被诱导并支持肠道病毒 A71 感染的人原代神经细胞中的病毒复制。
Sci Rep. 2020 Sep 17;10(1):15234. doi: 10.1038/s41598-020-71970-3.
4
Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.HIV-1 逆转录酶中 181 位氨基酸突变导致非核苷类逆转录酶抑制剂高敏性和耐药性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00676-19. Print 2019 Aug.
5
Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.芳基取代苯并咪唑酮类作为强效HIV-1非核苷类逆转录酶抑制剂
ACS Med Chem Lett. 2019 Jan 17;10(2):196-202. doi: 10.1021/acsmedchemlett.8b00549. eCollection 2019 Feb 14.
6
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.HIV-1 非核苷类逆转录酶抑制剂(NNRTIs)从实验室到临床的历程。
J Med Chem. 2019 May 23;62(10):4851-4883. doi: 10.1021/acs.jmedchem.8b00843. Epub 2018 Dec 27.
7
Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitors.噻吩[3,2-d]嘧啶类非核苷 HIV-1 RT 抑制剂强效广谱抑制作用的结构基础。
Elife. 2018 Jul 25;7:e36340. doi: 10.7554/eLife.36340.
8
Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review.HIV-1 逆转录酶抑制剂耐药性的分子对接研究:综述
Molecules. 2018 May 21;23(5):1233. doi: 10.3390/molecules23051233.
9
The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.FIV 逆转录酶的结构及其对非核苷抑制剂耐药性的影响。
PLoS Pathog. 2018 Jan 24;14(1):e1006849. doi: 10.1371/journal.ppat.1006849. eCollection 2018 Jan.
HIV-1 逆转录酶与抗病毒药物耐药性。第 1 部分。
Curr Opin Virol. 2013 Apr;3(2):111-8. doi: 10.1016/j.coviro.2013.03.012. Epub 2013 Apr 19.
4
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.HIV-1 逆转录酶与抗病毒药物耐药性。第 2 部分。
Curr Opin Virol. 2013 Apr;3(2):119-28. doi: 10.1016/j.coviro.2013.03.014. Epub 2013 Apr 19.
5
Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.新型非核苷类逆转录酶抑制剂 MK-6186 的抗病毒活性和体外突变发展途径。
Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35. doi: 10.1128/AAC.00102-12. Epub 2012 Mar 5.
6
HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.HIV-1 逆转录酶-DNA-奈韦拉平复合物揭示非核苷抑制机制。
Nat Struct Mol Biol. 2012 Jan 22;19(2):253-9. doi: 10.1038/nsmb.2223.
7
Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.非核苷类逆转录酶抑制剂体外耐药选择过程中非 B 型 HIV-1 的不同突变途径。
Antimicrob Agents Chemother. 2010 Nov;54(11):4812-24. doi: 10.1128/AAC.00829-10. Epub 2010 Aug 30.
8
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review.撒哈拉以南非洲地区抗逆转录病毒治疗项目中成年患者的病毒学随访:系统评价。
Lancet Infect Dis. 2010 Mar;10(3):155-66. doi: 10.1016/S1473-3099(09)70328-7.
9
Purification of untagged HIV-1 reverse transcriptase by affinity chromatography.
Protein Expr Purif. 2010 Jun;71(2):231-9. doi: 10.1016/j.pep.2010.01.001. Epub 2010 Jan 8.
10
Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.非多态性人类免疫缺陷病毒 1 型蛋白酶和逆转录酶治疗选择突变。
Antimicrob Agents Chemother. 2009 Nov;53(11):4869-78. doi: 10.1128/AAC.00592-09. Epub 2009 Aug 31.